The latest price target for Passage Bio (NASDAQ:PASG) was reported by Rodman & Renshaw on September 3, 2024. The analyst firm set a price target for $7.00 expecting PASG to rise to within 12 months (a possible 885.92% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Passage Bio (NASDAQ:PASG) was provided by Rodman & Renshaw, and Passage Bio initiated their buy rating.

There is no last upgrade for Passage Bio

The last downgrade for Passage Bio Inc happened on March 8, 2022 when JP Morgan changed their price target from N/A to N/A for Passage Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on September 3, 2024 so you should expect the next rating to be made available sometime around September 3, 2025.

While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a initiated with a price target of $0.00 to $7.00. The current price Passage Bio (PASG) is trading at is $0.71, which is within the analyst’s predicted range.